ArticleEpilepsia2026
Patterns of seizure frequency reduction in clinical trial participants with lower baseline seizure frequency.
Article in Epilepsia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveInclusion and exclusion criteria of clinical trials for seizures aim to select representative participants with a high enough seizure frequency to evaluate the efficacy of treatment in a relatively short double-blind period. To inform the selection of seizure frequency-based inclusion criteria, we evaluated the association between baseline seizure frequency and reduction of seizure frequency in the double-blind period.
methodsUsing data from 11 double-blind placebo-controlled trials of antiseizure medications for either focal or generalized onset epilepsy, we evaluated the association of baseline seizure frequency with 50% responder rate and percent reduction of seizure frequency in maintenance. We identified four patterns based on the presence or absence of significant association (p < .05) in placebo, active treatment, both, and neither. We also evaluated whether the time to prerandomization monthly seizure count (T-PSC) design impacted these associations.
resultsIn 55% of trials (6/11), there was no significant association of maintenance seizure frequency change with baseline seizure frequency. In 19% of trials (2/11), there were parallel elevations in placebo and active treatment responses for lower baseline seizure frequency. In one trial (1/11), that shift was observed in placebo only, whereas there was a ceiling effect of high response in levetiracetam. In the remaining 19% of trials (2/11), there were more seizure frequency reductions in lower baseline seizure frequencies in active treatment but not placebo. These associations were not modified when the T-PSC design was used. SIGNIFICANCE: The association of the magnitude of change in seizure frequency with baseline seizure frequency was inconsistent across trials. In eight of 11 trials, these patterns did not reduce the magnitude of difference between active treatment and placebo and thereby may not reduce statistical power. In only one trial did elevated placebo response reduce the difference between active treatment and placebo. In two trials, active treatment appeared more efficacious in lower seizure frequencies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.